Phase 2
N=152
Study of Arimoclomol in Inclusion Body Myositis (IBM)
Inclusion Body Myositis
Bottom Line
View on ClinicalTrials.gov: NCT02753530 ↗Enrolled (actual)
152
Serious AEs
19.2%
Results posted
May 2023
Primary outcome: Primary: Change in Inclusion Body Myositis Functional Rating Scale (IBMFRS) Total Score — -3.26; -2.26 score on a scale — p=0.1146
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Arimoclomol (Drug); Placebo (Other)
- Age
- Adult, Older Adult · 45+ yrs
- Sex
- All
- Sponsor
- ZevraDenmark
- Primary completion
- Jan 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Inclusion Body Myositis Functional Rating Scale (IBMFRS) Total Score |
-1.87; -1.03 | — |
| SECONDARY Change in Inclusion Body Myositis Functional Rating Scale (IBMFRS) Total Score |
-1.87; -1.03 | — |
| SECONDARY Grip Strength |
-1.09; -1.84; -3.93; -2.86 | — |
| SECONDARY Modified Timed up and go (mTUG) |
-0.075; -0.058; -0.084; -0.104 | — |
| SECONDARY Manual Muscle Testing (MMT), Total Score |
-0.49; -0.47; -0.48; -0.53 | — |
| SECONDARY 6 Minute Walk Test (6MWT); Distance After 6 Minutes (6MWD) |
-16.7; -10.7; -37.0; -30.9 | — |
| SECONDARY Short Form-36 (SF-36) Physical Component Score |
-1.3; -2.0; -1.0; -3.4 | — |
| SECONDARY Maximum Voluntary Isometric Contraction (MVICT) of Quadriceps |
-2.59; -2.49; -6.29; -4.67 | — |
| SECONDARY Health Assessment Questionnaire - Disability Index (HAQ-DI) |
0.24; 0.24; 0.33; 0.33 | — |
| SECONDARY 2 Minute Walk Test (2MWT) |
-4.73; -2.40; -11.18; -8.52 | — |
| SECONDARY Short Form-36 (SF-36) Mental Component Score |
-2.0; -2.1; -2.5; -1.3 | — |
| SECONDARY Patient Global Impression of Severity (PGIS) |
0; 1; 1; 3; 9; 12 | — |
| SECONDARY Patient Global Impression of Change (PGIC) |
1; 0; 10; 8; 27; 43 | — |
| SECONDARY Clinician Global Impression of Severity (CGIS) |
0; 0; 0; 0; 0; 2 | — |
| SECONDARY Clinician Global Impression of Change (CGIC) |
0; 0; 1; 0; 2; 5 | — |
| SECONDARY Falls and Near Falls |
4.8; 5.8; 9.1; 6.9 | — |
Summary
Funding Source - FDA Office of Orphan Products Development (OOPD). The purpose of this study is to evaluate the safety and efficacy of the study drug, arimoclomol in IBM patients.
Eligibility Criteria
Inclusion Criteria
- Meet any of the European Neuromuscular Centre Inclusion Body Myositis research diagnostic criteria 2011 categories for IBM.
- Demonstrate being able to arise from a chair without support from another person or device.
- Able to ambulate at least 20 ft/6 meters with or without assistive device. Once arisen from the chair, participant may use any walking device, i.e. walker/frame, can, crutches, or braces. They cannot be supported by another person and cannot use furniture or wall for support.
- Age at onset of weakness >45 years.
- Body weight of >= 40 kg.
- Able to give informed consent.
Exclusion Criteria
- History of any of the following excludes subject participation in the study: chronic infection particularly HIV or Hepatitis B or C; cancer other than basal cell cancer less than five years prior; or other chronic serious medical illnesses.
- Presence of any of the following on routine blood screening: White blood cells (WBC) 30 mg/dL; creatinine >1.5 x upper limit of normal; symptomatic liver disease with serum albumin 15x the upper limit of normal without any other explanation besides IBM.
- History of non-compliance with other therapies.
- Use of testosterone except for physiologic replacement doses in case of androgen deficiency. Participants must have documented proof of the androgen deficiency.
- Coexistence of other disease that would be likely to affect outcome measures
- Drug or alcohol abuse within past three months.
- Participation in a recent drug study in the last 30 days prior to the screening visit or use of a biologic agent less than 6 months prior to the screening visit.
- Women who are lactating or unwilling to use adequate method of birth control who are not surgically sterile. Adequate birth control includes use of intrauterine device, abstinence, or oral contraceptives or a double barrier method, e.g condom plus diaphragm will be necessary for both male and female participants.
- Participants taking >7.5 mg prednisolone or equivalent or participants on Intravenous Immunoglobulin Therapy (IVIg) or other immunosuppressants within the last 3 months.
- Clinically significant renal or hepatic disease, as indicated by clinical laboratory assessment.
Data sourced from ClinicalTrials.gov (NCT02753530). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.